Terminalia has been evaluated to a limited extent for its cardiovascular properties as well as for its role in cancer therapy. Hepatoprotective, cholesterol-reducing, and antioxidant effects have been described. However, there is limited clinical information is too limited to recommend Terminalia for any use.
Clinical studies have been conducted in coronary heart disease using T. arjuna bark extract at doses of 500 mg every 8 hours for up to 3 months. Dosages for other Terminalia species have not been clinically defined.